Sun Pharma has officially launched semaglutide injections in India under the brand names Noveltreat and Sematrinity. Noveltreat is priced between ₹900–₹2,000 per weekly dose for chronic weight management, while Sematrinity costs ₹750–₹1,300 weekly for type 2 diabetes. Both products feature advanced prefilled pen delivery systems.
On March 21, 2026, Sun Pharmaceutical Industries Limited announced the rollout of semaglutide injections in India. The launch follows DCGI approval earlier this year, allowing Sun Pharma to manufacture and market generic semaglutide for diabetes and obesity management. With competitive pricing, the company aims to expand access to advanced therapy for millions of Indian patients.
Product Details
• Noveltreat targets chronic weight management with five dose strengths
• Weekly therapy cost ranges from ₹900–₹2,000
• Sematrinity addresses type 2 diabetes with two dose strengths
• Weekly therapy cost ranges from ₹750–₹1,300
• Both brands use advanced prefilled pen delivery systems manufactured in Europe
Market Impact
India has one of the largest populations affected by diabetes and obesity. By introducing semaglutide at significantly lower prices compared to innovator brands, Sun Pharma is positioning itself as a leader in affordable advanced therapies. The launch is expected to boost adoption rates and provide patients with accessible treatment options.
Key Highlights
• Sun Pharma launches semaglutide injection in India on March 21, 2026
• Brands: Noveltreat (weight management) and Sematrinity (type 2 diabetes)
• Weekly therapy priced between ₹750–₹2,000
• Prefilled pen delivery system enhances convenience and usability
• Focus on affordability and accessibility in chronic disease care
Sources: Sun Pharma press release, ScanX News, InvestyWise